Zacks Investment Research lowered shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a hold rating to a sell rating in a research report sent to investors on Saturday, Zacks.com reports. They currently have $4.75 price target on the biotechnology company’s stock.
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
Several other research firms have also recently weighed in on ZIOP. HC Wainwright reissued a buy rating and set a $6.50 price objective on shares of ZIOPHARM Oncology in a research report on Wednesday, October 2nd. Raymond James set a $6.50 price objective on ZIOPHARM Oncology and gave the stock an outperform rating in a research report on Friday, November 8th. BidaskClub raised ZIOPHARM Oncology from a sell rating to a hold rating in a research report on Tuesday, October 29th. Finally, ValuEngine cut ZIOPHARM Oncology from a sell rating to a strong sell rating in a research report on Wednesday, October 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company has a consensus rating of Hold and an average price target of $6.45.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.34). On average, equities analysts anticipate that ZIOPHARM Oncology will post -0.33 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of ZIOP. Aperio Group LLC acquired a new position in ZIOPHARM Oncology in the 2nd quarter valued at approximately $35,000. Coastal Investment Advisors Inc. raised its holdings in ZIOPHARM Oncology by 427.5% in the 3rd quarter. Coastal Investment Advisors Inc. now owns 10,550 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 8,550 shares in the last quarter. Cadence Capital Management LLC acquired a new position in ZIOPHARM Oncology in the 3rd quarter valued at approximately $61,000. Niemann Capital Management Inc. acquired a new position in ZIOPHARM Oncology in the 2nd quarter valued at approximately $79,000. Finally, Prudential Financial Inc. raised its holdings in ZIOPHARM Oncology by 18.8% in the 2nd quarter. Prudential Financial Inc. now owns 16,673 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 2,640 shares in the last quarter. 38.58% of the stock is owned by hedge funds and other institutional investors.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.